Here, we report significant upregulation of RUNX3 (in A-172 and U-138 MG) and SFRP1 (in all three cell lines analyzed) after the treatment with NaBu and the combination treatment of CCM and NaBu. The gene discussed is SFRP1; the disease is cerebral cavernous malformation.